H
8622
vs
H
Hang Seng (Hong Kong)
Over the past 12 months, Huakang Biomedical Holdings Co Ltd has outperformed Hang Seng (Hong Kong), delivering a return of +13% compared to the Hang Seng (Hong Kong)'s +7% growth.
Stocks Performance
8622 vs Hang Seng (Hong Kong)
Performance Gap
8622 vs Hang Seng (Hong Kong)
Performance By Year
8622 vs Hang Seng (Hong Kong)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Huakang Biomedical Holdings Co Ltd
Glance View
Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 83 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.
